UNSPSC 51162415: Guaifenesin/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.

UNSPSC 51162415 Guaifenesin/phenylephrine is a Commodity code under which state and local governments procure specific pharmaceutical products, though recent solicitations tagged to this code show substantial scope misalignment. The two most active opportunities do not involve guaifenesin or phenylephrine combinations; instead, Seminole County, Florida is soliciting naloxone and drug deactivation systems for community health support, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing a multi-vendor contract framework for generic multi-source pharmaceuticals and OTC products broadly. State and local issuing bodies pursuing activity under this code include county health departments and state cooperative purchasing organizations that aggregate demand across multiple agencies and jurisdictions.

Geographically, recent activity centers on Florida and Minnesota, with MMCAP's multi-state cooperative framework extending to Oregon and potentially other allied jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, seeking annual supply of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and E-Verify compliance; and MMCAP's RFP S1070000015802, posted January 20, 2026, with proposals due March 26, 2026, requesting comprehensive generic pharmaceutical and OTC product pricing from manufacturers with cGMP and Drug Supply Chain Security Act certification, authorized wholesaler relationships, and performance tied to price competitiveness (75 percent weight) alongside administrative format compliance, EDI capability, and flat or net pricing options. Neither recent solicitation directly reflects the code's nominal scope, signaling limited current market activity for guaifenesin/phenylephrine as a standalone pharmaceutical line item in state and local procurement.